ANNEXON INC. - COMMON STOCK

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 مايو 2025 13:05:46 بحسب Nasdaq GlobeNewswire

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

12 مايو 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

09 مايو 2025 14:00:00 بحسب Nasdaq GlobeNewswire

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

07 مايو 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

16 أبريل 2025 13:05:18 بحسب Nasdaq GlobeNewswire

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

08 أبريل 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

03 أبريل 2025 15:18:29 بحسب Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

17 مارس 2025 13:05:37 بحسب Nasdaq GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

03 مارس 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

26 فبراير 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 فبراير 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

13 فبراير 2025 05:30:00 بحسب Nasdaq GlobeNewswire

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

13 يناير 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

10 يناير 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 يناير 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 ديسمبر 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

16 ديسمبر 2024 04:30:00 بحسب Nasdaq GlobeNewswire

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

05 ديسمبر 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

15 نوفمبر 2024 13:59:57 بحسب Nasdaq GlobeNewswire

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

14 نوفمبر 2024 05:00:00 بحسب Nasdaq GlobeNewswire